RxDoctor Payments Data

Laurie Desouza

Nurse Practitioner · Fort Myers, FLNPI 1487872826

Payments from drug & device makers

$4,191in general payments, 2019–2025

Across 179 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$486
  • AbbVie$417
  • Lilly USA, LLC$335
  • Amgen$326
  • AstraZeneca$322
  • Bayer$293
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,191100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,191 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$112,514
Medicare patients
319
Services billed
2,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$66,685
OzempicSemaglutide39$43,643
TrulicityDulaglutide19$27,240
ProliaDenosumab14$25,057
JardianceEmpagliflozin18$23,455
FarxigaDapagliflozin Propanediol11$16,035
VascepaIcosapent Ethyl15$7,260
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,308
Rosuvastatin Calcium270$2,105
Omeprazole102$1,657
Levothyroxine Sodium191$1,350
Atorvastatin Calcium175$1,288
Gabapentin61$1,207
Metoprolol Succinate96$1,141
Fenofibrate26$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$154$66,68557 claims
Novo NordiskOzempic$231$43,64339 claims
Lilly USA, LLCTrulicity$335$27,24019 claims
AmgenProlia$326$25,05714 claims
Boehringer IngelheimJardiance$52$23,45518 claims
AstraZenecaFarxiga$322$16,03511 claims
AbbVieSynthroid$417$44311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →